When was Outpace Bio founded?

Outpace Bio was founded in 2020 and raised its 1st funding round 1 year after it was founded.

Where is Outpace Bio located?

Outpace Bio is headquartered in Seattle, United States. It is registered at Seattle, Washington.

How many employees does Outpace Bio have?

As of Mar 31, 2026, the latest employee count at Outpace Bio is 71.

Is Outpace Bio a funded company?

Outpace Bio is a funded company, having raised a total of $200M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Mar 31, 2021.

When was the latest funding round of Outpace Bio?

Outpace Bio's latest funding was a $***** Series B round on Jul 17, 2024, with participation from 14 investors.

Where does Outpace Bio rank among its competitors?

Outpace Bio ranks 903rd amongst 3241 active competitors, of which 1114 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Outpace Bio, which secured $144M in Jul, 2024.

Who are the top competitors of Outpace Bio?

Outpace Bio's top competitors include Jazz Pharmaceuticals, Kite Pharma and Advanced Accelerator Applications. Among them, Outpace Bio secured the most recent funding round in July, 2024.

Outpace Bio - 2026 Company Profile, Team, Funding & Competitors

Outpace Bio is a series B company based in Seattle (United States), founded in 2020 by Scott Boyken and Marc Lajoie. It operates as a Developer of T-cell therapies for cancer treatment. Outpace Bio has raised $200M in funding from investors like RA Capital Management, Lyell Immunopharma and Artis Ventures. The company has 3241 active competitors, including 1114 funded and 782 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Kite Pharma and Advanced Accelerator Applications.

Company Details

Developer of T-cell therapies for cancer treatment. The therapies include cell therapy producing controlled Cytokine X, CAR with counter- exhaustion mechanism, cell therapy producing controlled Cytokine Y, and drug-induced gene regulation. These therapies are developed by combining protein design and cell engineering and also with the help of protein design software that custom designs the new biological functions.

Website: www.outpacebio.com/
Social
Registered Address: Seattle, Washington

Key Metrics

Founded Year

2020

Location

Seattle, United States

Stage

Series B

Total Funding

$200M in 2 rounds

Latest Funding Round

Series B, Jul 17, 2024, $*****

Investors

RA Capital Management & 16 more

Ranked

903^rd among 3241 active competitors

Employee Count

71 as on Mar 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3118 more

View Outpace Bio's full profile

Outpace Bio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
OUTPACE BIO, INC. CIN: 853122776 , United States, Active	Dec 31, 1999	-	58 (As on Dec 31, 2024)	-

Outpace Bio has raised a total funding of $200M over 2 rounds. Its first funding round was on Mar 31, 2021. Its latest funding round was a Series B round on Jul 17, 2024 for $*****. 14 investors participated in its latest round. Outpace Bio has 17 institutional investors.

Here is the list of recent funding rounds of Outpace Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 17, 2024	3199560	Series B	2116066	2299160	7305087	4736306
Mar 31, 2021	9031455	Series A	5861020	9458216	Artis Ventures & 1 more	Abstract Ventures & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of Outpace Bio's funding rounds and investors

The founders of Outpace Bio are Scott Boyken and Marc Lajoie.

Here are the details of Outpace Bio's key team members:

Scott Boyken: Co - Founder of Outpace Bio.
Contact Info: 1 email address
Marc Lajoie: Co - Founder & CEO of Outpace Bio.
Contact Info: 1 email address

View details of Outpace Bio's Founder profiles and Board Members

Outpace Bio's employee count trend

Outpace Bio has 71 employees as of Mar 26. Here is Outpace Bio's employee count trend over the years:

Uncover Outpace Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Outpace Bio include Jazz Pharmaceuticals, Kite Pharma and Advanced Accelerator Applications. Here is the list of Top 10 competitors of Outpace Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Prospect Venture Partners, Versant Ventures ... & 14 others	82/100
2nd	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Vivo Capital & 10 others	79/100
3rd	Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired	Novartis company, developing molecular nuclear medicine theranostics	$56.1M	Vivo Capital, Tamburi Investment Partners ... & 4 others	78/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, Google Ventures & 17 others	75/100
5th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	RA Capital Management, BB Biotech & 14 others	74/100
6th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
7th	Immunocore 2008, Abingdon (United Kingdom), Public	Developer of drugs based on T-Cell receptor technology for the treatment of cancer	$601M	BlackRock, General Atlantic & 50 others	74/100
8th	FibroGen 1993, San Francisco (United States), Public	Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology.	$215M	Adage Capital Management, Corriente Biotechnology Partners ... & 26 others	72/100
9th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	72/100
10th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	72/100
903rd	Outpace Bio 2020, Seattle (United States), Series B	Developer of T-cell therapies for cancer treatment	$200M	RA Capital Management, Citadel & 15 others	44/100